FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion

  1. Yichao Fan
  2. Jiao Yue
  3. Mengtao Xiao
  4. Han Han-Zhang
  5. Yao Vickie Wang
  6. Chun Ma
  7. Zhilin Deng
  8. Yingxiang Li
  9. Yanyan Yu
  10. Xinghao Wang
  11. Shen Niu
  12. Youjia Hua
  13. Zhiping Weng
  14. Peter Atadja
  15. En Li
  16. Bin Xiang  Is a corresponding author
  1. Novartis Institute for BioMedical Research, China
  2. Novartis Institutes for BioMedical Research, China
  3. Tongji University, China

Abstract

Tumor suppressor p53 prevents cell transformation by inducing apoptosis and other responses. Homozygous TP53 deletion occurs in various types of human cancers for which no therapeutic strategies have yet been reported. Based on TCGA database analysis, TP53 homozygous deletion locus mostly exhibits co-deletion of the neighboring gene FXR2, which belongs to the Fragile X gene family. Here, we demonstrate that inhibition of the remaining family member FXR1 selectively blocks cell proliferation in cancer cells containing homozygous deletion of both TP53 and FXR2 in a collateral lethality manner. Mechanistically, in addition to its RNA-binding function, FXR1 recruits transcription factor STAT1 or STAT3 to gene promoters at the chromatin interface and regulates transcription thus, at least partially, mediating cell proliferation. Our study anticipates that inhibition of FXR1 is a potential therapeutic approach to targeting human cancers harboring TP53 homozygous deletion.

Article and author information

Author details

  1. Yichao Fan

    Epigenetic Discovery, Novartis Institute for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  2. Jiao Yue

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Jiao Yue, Jiao Yue is an employee for Novartis, Inc., where part of the study was conducted..
  3. Mengtao Xiao

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Mengtao Xiao, Mengtao Xiao is an employee for Novartis, Inc., where part of the study was conducted..
  4. Han Han-Zhang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Han Han-Zhang, Han Han-Zhang is an employee for Novartis, Inc., where part of the study was conducted..
  5. Yao Vickie Wang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  6. Chun Ma

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  7. Zhilin Deng

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  8. Yingxiang Li

    Department of Bioinformatics, Tongji University, Shanghai, China
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0835-9280
  9. Yanyan Yu

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Yanyan Yu, Yanyan Yu is an employee for Novartis, Inc., where part of the study was conducted..
  10. Xinghao Wang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  11. Shen Niu

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Shen Niu, Shen Niu is an employee for Novartis, Inc., where part of the study was conducted..
  12. Youjia Hua

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Youjia Hua, Youjia Hua is an employee for Novartis, Inc., where part of the study was conducted..
  13. Zhiping Weng

    Department of Bioinformatics, Tongji University, Shanghai, China
    Competing interests
    No competing interests declared.
  14. Peter Atadja

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    Peter Atadja, Peter Atadja is an employee for Novartis, Inc., where part of the study was conducted..
  15. En Li

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    Competing interests
    No competing interests declared.
  16. Bin Xiang

    Epigenetic Discovery, Novartis Institutes for BioMedical Research, Shanghai, China
    For correspondence
    bin.xiang@novartis.com
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6973-100X

Funding

Novartis (Research)

  • Bin Xiang

Novartis (Postdoc program)

  • Yichao Fan

The authors declare that there was no funding for this work.

Ethics

Animal experimentation: All the procedures related to animal handling, care and the treatment in the study were performed according to the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of WuXi AppTec following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). The approved protocol number is R20150728-Mouse and Rat. The animals were daily checked for any effects of tumor growth and treatments on normal behavior such as mobility, food and water consumption, body weight gain/loss, eye/hair matting and any other abnormal effects. Death and observed clinical signs were recorded.

Copyright

© 2017, Fan et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,054
    views
  • 455
    downloads
  • 28
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yichao Fan
  2. Jiao Yue
  3. Mengtao Xiao
  4. Han Han-Zhang
  5. Yao Vickie Wang
  6. Chun Ma
  7. Zhilin Deng
  8. Yingxiang Li
  9. Yanyan Yu
  10. Xinghao Wang
  11. Shen Niu
  12. Youjia Hua
  13. Zhiping Weng
  14. Peter Atadja
  15. En Li
  16. Bin Xiang
(2017)
FXR1 regulates transcription and is required for growth of human cancer cells with TP53/FXR2 homozygous deletion
eLife 6:e26129.
https://doi.org/10.7554/eLife.26129

Share this article

https://doi.org/10.7554/eLife.26129

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Rosalyn W Sayaman, Masaru Miyano ... Mark A LaBarge
    Research Article Updated

    Effects from aging in single cells are heterogenous, whereas at the organ- and tissue-levels aging phenotypes tend to appear as stereotypical changes. The mammary epithelium is a bilayer of two major phenotypically and functionally distinct cell lineages: luminal epithelial and myoepithelial cells. Mammary luminal epithelia exhibit substantial stereotypical changes with age that merit attention because these cells are the putative cells-of-origin for breast cancers. We hypothesize that effects from aging that impinge upon maintenance of lineage fidelity increase susceptibility to cancer initiation. We generated and analyzed transcriptomes from primary luminal epithelial and myoepithelial cells from younger <30 (y)ears old and older >55 y women. In addition to age-dependent directional changes in gene expression, we observed increased transcriptional variance with age that contributed to genome-wide loss of lineage fidelity. Age-dependent variant responses were common to both lineages, whereas directional changes were almost exclusively detected in luminal epithelia and involved altered regulation of chromatin and genome organizers such as SATB1. Epithelial expression variance of gap junction protein GJB6 increased with age, and modulation of GJB6 expression in heterochronous co-cultures revealed that it provided a communication conduit from myoepithelial cells that drove directional change in luminal cells. Age-dependent luminal transcriptomes comprised a prominent signal that could be detected in bulk tissue during aging and transition into cancers. A machine learning classifier based on luminal-specific aging distinguished normal from cancer tissue and was highly predictive of breast cancer subtype. We speculate that luminal epithelia are the ultimate site of integration of the variant responses to aging in their surrounding tissue, and that their emergent phenotype both endows cells with the ability to become cancer-cells-of-origin and represents a biosensor that presages cancer susceptibility.

    1. Cancer Biology
    Yiwei Huang, Gujie Wu ... Cheng Zhan
    Research Article

    Chemotherapy is widely used to treat lung adenocarcinoma (LUAD) patients comprehensively. Considering the limitations of chemotherapy due to drug resistance and other issues, it is crucial to explore the impact of chemotherapy and immunotherapy on these aspects. In this study, tumor samples from nine LUAD patients, of which four only received surgery and five received neoadjuvant chemotherapy, were subjected to scRNA-seq analysis. In vitro and in vivo assays, including flow cytometry, immunofluorescence, Seahorse assay, and tumor xenograft models, were carried out to validate our findings. A total of 83,622 cells were enrolled for subsequent analyses. The composition of cell types exhibited high heterogeneity across different groups. Functional enrichment analysis revealed that chemotherapy drove significant metabolic reprogramming in tumor cells and macrophages. We identified two subtypes of macrophages: Anti-mac cells (CD45+CD11b+CD86+) and Pro-mac cells (CD45+CD11b+ARG +) and sorted them by flow cytometry. The proportion of Pro-mac cells in LUAD tissues increased significantly after neoadjuvant chemotherapy. Pro-mac cells promote tumor growth and angiogenesis and also suppress tumor immunity. Moreover, by analyzing the remodeling of T and B cells induced by neoadjuvant therapy, we noted that chemotherapy ignited a relatively more robust immune cytotoxic response toward tumor cells. Our study demonstrates that chemotherapy induces metabolic reprogramming within the tumor microenvironment of LUAD, particularly affecting the function and composition of immune cells such as macrophages and T cells. We believe our findings will offer insight into the mechanisms of drug resistance and provide novel therapeutic targets for LUAD in the future.